167 related articles for article (PubMed ID: 20700124)
1. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.
Cocco E; Hu Z; Richter CE; Bellone S; Casagrande F; Bellone M; Todeschini P; Krikun G; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Buza N; Pecorelli S; Lockwood CJ; Santin AD
Br J Cancer; 2010 Sep; 103(6):812-9. PubMed ID: 20700124
[TBL] [Abstract][Full Text] [Related]
2. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.
Cocco E; Varughese J; Buza N; Bellone S; Glasgow M; Bellone M; Todeschini P; Carrara L; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Lockwood CJ; Santin AD
BMC Cancer; 2011 Jun; 11():263. PubMed ID: 21693061
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
Cocco E; Varughese J; Buza N; Bellone S; Lin KY; Bellone M; Todeschini P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Carrara L; Tassi R; Pecorelli S; Lockwood CJ; Santin AD
Clin Exp Metastasis; 2011 Oct; 28(7):689-700. PubMed ID: 21725665
[TBL] [Abstract][Full Text] [Related]
4. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.
Varughese J; Cocco E; Bellone S; de Leon M; Bellone M; Todeschini P; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2011 Jul; 117(14):3163-72. PubMed ID: 21246534
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
8. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
[TBL] [Abstract][Full Text] [Related]
10. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.
Santin AD; Zhan F; Cane' S; Bellone S; Palmieri M; Thomas M; Burnett A; Roman JJ; Cannon MJ; Shaughnessy J; Pecorelli S
Br J Cancer; 2005 Apr; 92(8):1561-73. PubMed ID: 15785748
[TBL] [Abstract][Full Text] [Related]
11. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.
Cocco E; Bellone S; El-Sahwi K; Cargnelutti M; Casagrande F; Buza N; Tavassoli FA; Siegel ER; Visintin I; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2009 Jul; 101(2):335-41. PubMed ID: 19536090
[TBL] [Abstract][Full Text] [Related]
12. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.
Paik D; Cocco E; Bellone S; Casagrande F; Bellone M; Siegel EE; Richter CE; Schwartz PE; Rutherford TJ; Santin AD
Gynecol Oncol; 2010 Oct; 119(1):140-5. PubMed ID: 20673976
[TBL] [Abstract][Full Text] [Related]
13. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Gokden M; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Br J Cancer; 2004 May; 90(9):1814-24. PubMed ID: 15208622
[TBL] [Abstract][Full Text] [Related]
14. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.
Bellone S; Watts K; Cane' S; Palmieri M; Cannon MJ; Burnett A; Roman JJ; Pecorelli S; Santin AD
Gynecol Oncol; 2005 Jul; 98(1):92-8. PubMed ID: 15904949
[TBL] [Abstract][Full Text] [Related]
15. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Varughese J; Cocco E; Bellone S; Bellone M; Todeschini P; Carrara L; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Gynecol Oncol; 2011 Jul; 122(1):171-7. PubMed ID: 21453957
[TBL] [Abstract][Full Text] [Related]
16. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody.
Bellone M; Cocco E; Varughese J; Bellone S; Todeschini P; El-Sahwi K; Carrara L; Guzzo F; Schwartz PE; Rutherford TJ; Pecorelli S; Marshall DJ; Santin AD
Int J Gynecol Cancer; 2011 Aug; 21(6):1084-90. PubMed ID: 21633302
[TBL] [Abstract][Full Text] [Related]
17. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
[TBL] [Abstract][Full Text] [Related]
19. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
20. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
